PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Sponsor
Cancer Trials Ireland
Study ID
NCT05518110
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trametinib — DRUG
    2mg of Trametinib (orally) daily.
  • Hydroxychloroquine — DRUG
    1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.

Study Details

This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.

Key Dates

Start date
May 31, 2023
Status verified
Apr 2026
Primary completion
Mar 3, 2026
Completion
Mar 3, 2026

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PaTcH
    All eligible patients will be treated with trametinib 2mg and hydroxychloroquine 1200mg daily (600mg twice a day (BID)) orally. Treatment will be continuous in treatment cycles lasting 28 days, and will continue until radiological or clinical progression of disease, unacceptable toxicity or consent withdrawal.

Primary Outcome Measure

Patients free of disease progression [ Time Frame: Twelve weeks from starting treatment. ]

Related Studies